Novel Technology Expands the Power of DIA-MS
Download this whitepaper to review the exciting technology behind the advances in data independent acquisition and explore how it can enhance your research.
Batch-to-Batch Consistency of Premium Grade Bioactive Proteins
Many novel cell and gene therapies have the potential to offer personalized therapeutic approaches and hold great promise for curing or treating diseases.
Non-Invasive Monitoring of Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD), a liver condition that is characterized by liver steatosis accompanied by liver cell injury and inflammation.
Detection Of Low-Abundance Serum Proteins Associated With Prediabetes For Predictive And Prognostic Purposes
Download this whitepaper to uncover predicting disease onset via clinical biomarkers as well as other potential applications in diabetes research.
Confident RNA Sample Quality Control and Fragment Analysis.
This whitepaper, including 15 peer-reviewed publications across various RNA applications, demonstrates how researchers used automated electrophoresis for sample quality control and fragment analysis to ensure high-quality RNA and cDNA samples.
The Battle Against COVID-19
The battle against COVID-19 only begins with a test to identify who is infected and who is not. To accelerate an effective response, we have to move beyond the initial diagnosis to prognosis: Who is most susceptible to developing serious, life-threatening symptoms?
Zeno Trap: Defining New Levels of Sensitivity
Download this whitepaper to discover a system that enhances sensitivity and maintains high resolution, fast scan speed as well as a wide dynamic range.
Protein Biomarkers Show Promise in Predicting Patient Response to Cancer Immunotherapies
Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.
Accelerating Cancer Immune Cell Therapies
As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.
Challenging Host Cell Protein Assays for Improved Risk Mitigation
At high levels, host cell proteins (HCPs) can cause immunogenic responses and reduced efficacy of biologics, so it is imperative to have an effective, robust HCP assay to detect them and mitigate these effects.